Cyclin D3 restricts SARS‐CoV‐2 envelope incorporation into virions and interferes with viral spread |
| |
Authors: | Ravi K Gupta Petra Mlcochova |
| |
Affiliation: | 1. Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge UK ; 2. Department of Medicine, University of Cambridge, Cambridge UK ; 3. Africa Health Research Institute, Durban South Africa |
| |
Abstract: | The COVID‐19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) presents a great threat to human health. The interplay between the virus and host plays a crucial role in successful virus replication and transmission. Understanding host–virus interactions are essential for the development of new COVID‐19 treatment strategies. Here, we show that SARS‐CoV‐2 infection triggers redistribution of cyclin D1 and cyclin D3 from the nucleus to the cytoplasm, followed by proteasomal degradation. No changes to other cyclins or cyclin‐dependent kinases were observed. Further, cyclin D depletion was independent of SARS‐CoV‐2‐mediated cell cycle arrest in the early S phase or S/G2/M phase. Cyclin D3 knockdown by small‐interfering RNA specifically enhanced progeny virus titres in supernatants. Finally, cyclin D3 co‐immunoprecipitated with SARS‐CoV‐2 envelope (E) and membrane (M) proteins. We propose that cyclin D3 impairs the efficient incorporation of envelope protein into virions during assembly and is depleted during SARS‐CoV‐2 infection to restore efficient assembly and release of newly produced virions. |
| |
Keywords: | assembly, cell cycle, cyclin D3, Fucci, SARS‐ CoV‐ 2 |
|
|